Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students

  • Posted by: Biocon Biologics

U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India

  • Posted by: Biocon Biologics

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%

  • Posted by: Biocon Biologics

Deepali Naair Appointed as the Global Head – Brand & Corporate Communications at Biocon Biologics

  • Posted by: Biocon Biologics

Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia

  • Posted by: Biocon Biologics

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

  • Posted by: Biocon Biologics

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics Expands Insulin Access in Malaysia

  • Posted by: Biocon Biologics

Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025

  • Posted by: Biocon Biologics